FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
Global IT services provider FPT and Pharma Group jointly hosted the Healthcare Innovation Forum - HIF 2025. The event served as a multi-stakeholder dialogue platform with a spotlight on breakthrough innovations in science, technology, and AI to accelerate healthcare advancements and drive digital transformation in public health services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606137635/en/
FPT Proposes Public-Private Partnership Model to Develop Vietnam's Digital Healthcare Ecosystem
The Forum was attended by Vietnam Deputy PM H.E. Le Thanh Long, key government officials, and international guests including U.S. Ambassador Marc Knapper, Swiss Ambassador Thomas Gass, former German Vice Chancellor Dr. Philipp Rösler, and representatives from Japan, Singapore, and Harvard Medical School.
Vietnam Deputy PM H.E. Le Thanh Long stressed the urgent need to reform healthcare, outlining five strategies: accelerate digitalization with AI and IoT; boost biotech research; strengthen the pharmaceutical sector; foster public–private partnerships; and expand international cooperation for a modern digital health system.
Mr. Darrell Oh, Chairman of Pharma Group, said: 'Pharma Group, representing the innovative pharmaceutical industry, reaffirms its commitment to supporting Vietnam in achieving the goals outlined in Vision 2045. Realizing this ambition requires a unified, multi-stakeholder approach. Only through sustained collaboration can policy be translated into impactful, lasting improvements in public health. Investing in healthcare is, ultimately, an investment in Vietnam's most vital asset: its people.'
Dr. Truong Gia Binh, FPT Chairman, stated: 'To accompany Vietnam's new era of advancement, the healthcare sector must achieve breakthroughs in three areas: regulation, innovation, and public–private collaboration. We must shift from restrictive thinking to viewing regulation as a driver of national competitiveness, ensuring faster access to new medicines, like in the U.S. or Japan. Vietnam can become a hub for AI-powered clinical trials and drug development, leveraging its strong tech talent with 1 million IT workers, aiming for half to be AI-proficient. Public–private partnerships must connect hospitals, pharmaceutical firms, and healthcare professionals through shared data platforms. Just as Vietnam rose to global prominence in software, it can now aim to lead in innovative pharmaceuticals - one of the world's most advanced industries.'
AI in Pharma: A Global Trend and an Opportunity for Vietnam
Recent data shows 80% of pharma professionals use AI for drug discovery, with 95% of companies investing in it; and AI can cut drug development time from 5-6 years to one. In clinical trials, AI can reduce costs by 70% and timelines by 80%.
Mr. Hoang Viet Anh, FPT Digital Chairman and FPT Telecom Chairman, FPT Corporation, underscored: 'AI and GenAI are transforming the pharmaceutical industry, with key benefits including accelerating new drug development and enhancing clinical trials across the value chain.' He also called this a key moment for digital transformation, outlining an AI roadmap for Vietnam's pharmaceutical sector through 2028. Plans include a centralized data system and AI lab pilots in 2025, blockchain trials in 2026 to fight counterfeit drugs, and a 20% reduction in drug trial time by 2027, aiming to become ASEAN's leading AI hub by 2028.
Achieving Resolution 57 and National Goals for Healthcare Breakthroughs
As Vietnam pursues its 2045 high-income vision, healthcare emerges as a key pillar for quality of life, social security, and sustainable growth. The round table discussing critical factors to achieve Resolution 57 objectives emphasized three key messages. Firstly, AI and big data drive healthcare innovation, enabling faster drug development and personalized care. Secondly, bold legal and institutional reforms are essential to match tech advances, including streamlined approvals and flexible data regulations. Lastly, strong public-private collaboration is vital to build a sustainable innovation ecosystem connecting tech firms, hospitals, research institutes, and startups.
Mr. Vu Anh Tu, FPT Chief Technology Officer, commented: 'AI is set to transform healthcare, and by creating a centralized health data infrastructure and leveraging AI and data analysis for new drug trials, Vietnam can establish advanced clinical research centers, shorten timelines, reduce costs, and expand public access to new medicines. Technology can also enable new healthcare delivery models like telemedicine hospitals to improve primary healthcare and expand public access.'
He further stated: 'FPT is ready to collaborate with startups, major enterprises, and global AI research institutions to address key challenges through AI. This approach will mobilize domestic and international resources to drive breakthroughs in this new era.'
About Pharma Group
Founded in 1998, Pharma Group represents the innovative pharmaceutical industry in Vietnam, comprising 20 member companies from Europe, the United States, and Japan. These companies share a mission to ensure timely and sustainable access to high-quality, safe, and innovative medicines for Vietnamese patients.
Pharma Group operates under the European Chamber of Commerce in Vietnam (EuroCham) and is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). It works closely with policymakers and healthcare stakeholders in Vietnam and globally to advance sustainable health policies and initiatives, reduce the time to patient access, and build a favorable and attractive investment environment.
About FPT Corporation
FPT Corporation is Vietnam's leading technology group, pioneering digital transformation and leading in technology and telecommunications solutions and services. FPT supports clients in over 30 countries and territories in achieving their business development strategies through technology.
In the healthcare sector, FPT is committed to building a remote healthcare platform and a comprehensive digital medical ecosystem that delivers fast, convenient, and integrated services for regulators, medical institutions, pharmaceutical companies, pharmacy networks, and the public. Leveraging over a decade of AI research and development, FPT actively integrates AI technologies to enhance healthcare quality and expand access to personalized medical services, particularly through telemedicine and real-time patient health monitoring. In pharmaceuticals, FPT advances the sector by digitizing R&D processes, deploying Advanced Pharmacy Omni-Channel Systems, and developing comprehensive drug management platforms connecting patients, doctors, and pharmacies through electronic medical records. Prominent clients include Long Chau Pharmacy, Hitachi Medical Devices, Olympus, MedAdvisor, Zuellig Pharma, and BrightInsight.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250606137635/en/
CONTACT: Media Contact
Mai Duong (Ms.)
FPT Corporation
FPT Software PR Manager
[email protected]
KEYWORD: VIET NAM SOUTHEAST ASIA ASIA PACIFIC
INDUSTRY KEYWORD: TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE HEALTH PHARMACEUTICAL DATA MANAGEMENT ARTIFICIAL INTELLIGENCE
SOURCE: FPT Corporation
Copyright Business Wire 2025.
PUB: 06/06/2025 07:13 AM/DISC: 06/06/2025 07:12 AM
http://www.businesswire.com/news/home/20250606137635/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP)
Papzimeos, the first-ever treatment approved for RRP is a moment for celebration and reflection FORT WORTH, Texas, August 15, 2025--(BUSINESS WIRE)--The Recurrent Respiratory Papillomatosis Foundation (RRPF) is excited to share the news that the U.S. Food and Drug Administration (FDA) has granted full approval to Precigen's Papzimeos (zopapogene imadenovec-drba) under Priority Review for the treatment of adults with Recurrent Respiratory Papillomatosis (RRP). Papzimeos is the first and only FDA-approved treatment for RRP. (See FDA's announcement here) A moment of profound healing for the RRP Community This is truly a remarkable day – the culmination of decades of advocacy, resilience, and unwavering commitment from patients, families, researchers, and supporters. The approval of the first non-surgical treatment for adults with RRP marks not only a scientific milestone, but an inflection point for the entire RRP community. We extend our deepest gratitude to the many individuals and institutions who helped make this breakthrough possible – from the investigators, NIH collaborators, and clinicians who advanced the science, to the industry partners, whose investment and commitment to this community helped bring this treatment to approval. The FDA's announcement is also a deeply personal victory for every voice that has spoken up, every surgery endured, and every hope held steadfast. At RRPF, we are honored to walk alongside this community, championing awareness, supporting research, and amplifying the lived experiences of those affected by this rare disease. We celebrate the light this approval brings and recommit ourselves to the journey ahead, ensuring that patients of every age and living beyond the U.S. can one day access safe, effective and nonsurgical treatments. "For decades, our community has persevered through an isolating journey of countless surgeries, silence, and uncertainty. Yet while we continued to breathe, we continued to hope. Today, our hope is realized. Today, with the approval of Papzimeos our hope is no longer a dream, it's a reality," said Kim McClellan, President of RRPF. "This is a moment of profound healing, not just for the body, but for the spirit of every adult living with RRP. We finally have an FDA-approved treatment that targets the root cause of RRP and with it, the chance for many members of our community to reclaim lives unencumbered by RRP." Quick facts about Papzimeos (zopapogene imadenovec-drba): The first and only FDA-approved treatment for RRP Approved for adults with RRP The only treatment to target the underlying cause of RRP Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11 Delivered via four subcutaneous injections over a 12-week interval Patients can access Papzimeos SUPPORT for personalized services including insurance navigation, financial assistance, and ongoing access support, by calling (866) 827-8180. For Precigen's full release here: Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis For those interested in learning more about resources available to individuals affected by RRP, visit Renewed hope and continued commitment The FDA full approval of Papzimeos is a monumental step forward for the RRP community, but it is not the final destination. RRPF remains deeply committed to advancing research for all patients – including pediatric patients, who continue to face burdens of this disease without an approved therapeutic option, and patients around the world. This milestone fuels our resolve and fortifies our determination to see a future where all people living with RRP have the same hope realized. With strengthened movement, we will continue to advocate, collaborate, and push for the science that brings healing at every age and to every corner of the world. About RRPF The Recurrent Respiratory Papillomatosis Foundation (RRPF) was born from a parent's urgent need to understand and confront a rare, chronic, and potentially life-threatening disease affecting their child. Since 1991, RRPF has been a lifeline for patients and families navigating the isolating journey of RRP – offering connection, advocacy, and hope. What began as a grassroots effort has grown into a mission-driven organization united by the voices of parents, patients, and researchers. RRPF provides vital resources including access to the latest research, updates on clinical trials and medical meetings, and a supportive community for those affected by RRP. The foundation has played a pivotal role in advancing scientific understanding of RRP – contributing to research as authors, funders, and collaborators across multiple studies and initiatives. RRPF honors the legacy of those like Jennifer Woo, a former president of RRPF whose life and career were dedicated to curing RRP, and continues to drive forward research, awareness, and support for all those impacted. While we breathe, we hope. Learn more here: View source version on Contacts Media:Kim McClellan, President RRPF(331) 826-9050kimmc@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
IKS Health Wins Google Cloud Award for its Care Enablement Platform for Augmenting Human Expertise with AI
DALLAS, August 15, 2025--(BUSINESS WIRE)--IKS Health, a global leader in care enablement solutions supporting clinicians, staff, and patients at every step of the care journey, is proud to announce its Care Enablement Platform has won a Google Cloud 2025 DORA Award for "Augmenting Human Expertise with AI." IKS Health's Care Enablement Platform is a technology-powered ecosystem that combines advanced automation, data intelligence, and human expertise to offload administrative, clinical, and operational tasks. Its unique human + AI model is a seamless fusion of intelligent automation with domain-expert intervention to ensure accuracy and empathy. "Our goal is to alleviate the increasing administrative and operational burdens faced by clinicians, and our team is proud to achieve recognition from Google Cloud for our AI-human hybrid model that delivers superior accuracy, empathy, and trust compared to standalone automation," said Vijay Venkatesan, Chief Technology Officer, IKS Health. Google Cloud's DORA Awards celebrate the technical excellence and elite performance that is possible with software development and delivery. The IKS Health AI + human model accelerates delivery, cuts delays, reduces errors, and minimizes downtime, driving faster innovation and more reliable operations. "We are honored to receive such a prestigious award from Google Cloud for our advanced work in the 'Augmenting Human Expertise with AI' category," said Sachin K. Gupta, Founder and Global CEO, IKS Health. "Validation of our goal to create a platform-based solution that healthcare organizations can rely on to scale operations fuels us to continue the work of transforming healthcare so that clinicians can focus on their core work." About IKS Health IKS Health takes on the chores of healthcare — spanning administrative, clinical, and operational burdens — so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health's global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit Inventurus Knowledge Solutions Limited is listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). {Scrip codes: NSE - IKS and BSE - 544309} View source version on Contacts MEDIA CONTACT - IKS HEALTH Jill Gross, Director of Public Relationspress@
Business Wire
6 hours ago
- Business Wire
Next Health Announces Calabasas Expansion With Grand Opening August 15, 2025
WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Next Health, the world's most advanced brand of proactive healthcare centers, is expanding its Los Angeles footprint with a new flagship location in Calabasas. Doors are already open, with an official Grand Opening celebration set for Friday, August 15, 2025. This expansion supports Next Health's mission to bring health optimization and longevity to the most strategic wellness-forward markets in the U.S., empowering individuals to take a proactive approach to their health. Next Health, the world's most advanced brand of proactive healthcare centers, is expanding its Los Angeles footprint with a new flagship location in Calabasas. The Grand Opening will feature a ribbon-cutting ceremony and exclusive wellness panel moderated by Next Health Founder and CEO Dr. Darshan Shah, who will lead a discussion on the future of longevity. He will be joined by wellness entrepreneur, fitness icon, and long-time Next Health supporter Brooke Burke, who will share insights into her personal health journey and the lifestyle practices that fuel her approach to longevity and vitality. The Calabasas location is led by powerhouse franchise partners Barry and Lori Turbow, along with Donnie and Megan Wilson —experienced entrepreneurs whose careers span success in sports marketing, business development, and healthcare. For Lori, a trained occupational therapist, the venture is deeply personal, shaped by her own experience navigating chronic illness and a lifelong passion for helping others reclaim their health. 'We're proud to bring Next Health to Calabasas—a community that embodies innovation, vitality, and a deep commitment to wellness,' said Barry and Lori Turbow. 'After years of working in healthcare and overcoming personal challenges, we knew we wanted to create a space where people can take charge of their longevity, access breakthrough medical technologies, and experience proactive health in a whole new way.' The center offers a comprehensive suite of services, including IV Therapy, hormone optimization, peptide therapy, hyperbaric oxygen chamber, weight optimization programs, cryotherapy, ozone therapy (including EBOO: Extracorporeal Blood Oxygenation and Ozonation), Therapeutic Plasma Exchange (TPE), and Next Health's most advanced longevity protocols like Executive Physicals, Biological Age Testing, and extensive functional medicine testing. Calabasas was chosen for its concentration of health-conscious residents, influential wellness culture, and demand for proactive medical solutions in a luxury setting. The new location reflects the collaborative vision of Dr. Darshan Shah, CEO and Founder of Next Health, and Kevin Peake, President, who continue to guide the brand's rapid national expansion through carefully selected franchise partners. 'Next Health Calabasas will serve as a beacon of health optimization in Southern California,' said Shah and Peake in a joint statement. 'We are thrilled to partner with Barry and Lori Turbow and Donnie and Megan Wilson to introduce cutting-edge longevity services to this remarkable community. Our goal is to empower individuals to take control of their health and extend the human healthspan through personalized, data-driven care.' Next Health Calabasas is located in the El Camino Shopping Center, offering a state-of-the-art, hospitality-grade facility designed to make advanced wellness accessible, empowering, and luxurious. Guests are invited to experience the future of health firsthand, with personalized consultations, immersive programming, and exclusive opening-week specials to mark the occasion. Location: 23383 Mulholland Dr, Woodland Hills, CA 91364 About Next Health Next Health is a pioneer in personalized health optimization and longevity. Founded in 2016 by renowned surgeon Dr. Darshan Shah and entrepreneur Kevin Peake, the brand blends advanced medical innovation with hospitality-grade experiences to help people live healthier, longer lives. Through services like IV therapy, hormone optimization, peptide treatments, cryotherapy, and extensive functional medicine testing, Next Health empowers people to take control of their vitality from the inside out.
